photobiomodulation therapy(low level LASER therapy) in heart failure

The effects of photobiomodulation therapy(low level LASER therapy) on functional capacity and quality of life of patients with heart failure reduced ejection fraction who are on cardiac rehabilitation programs : (double blind randomized )

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191207045638N1

Enrollment

Registered

2019-12-10

Start date

2019-08-23

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure reduced ejection fraction. Heart failure

Interventions

Intervention 1: Intervention group: ?Active LASER group(n=15)The intervention group will received low level LASER therapy ( LASER device: GALALAS,650nm,5Mw) before sub maximal aerobic exercise(cycl

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Expressed readiness to comply with all study procedures and availability for the duration of the study Provision of dated and signed informed consent form Age 18-65 years A diagnosis of heart failure reduced ejection fraction (LVEF= 40%) due to ischemic or non-ischemic etiology Optimal guideline directed medical therapies including angiotensin-converting enzymeinhibitors, ß-blockers, aldosterone antagonists, and diuretics for at least 3 months NewYork Heart association function class (NYHA Class) II-III

Exclusion criteria

Exclusion criteria: History of hospitalization for any cause including acute heart failure in preceding month presence Chronic renal failure or dialysis presence of chronic hepatic failure presence of neuromuscular disorders Presence of severe chronic pulmonary disease The patients who have pace maker, intracardiac defibrillator (ICD)or cardiac resynchronization therapy(CRT) psychiatric conditions inability to perform 6 minutes walk test Cardiomyopathy secondary to cancer therapy Presence of any hematologic , Rheumatologic disorder

Design outcomes

Primary

Measure	Time frame
NewYork Heart Association functional class, Physical performance( 6 minutes walk test distance). Timepoint: Before intervention and after completion of intervention. Method of measurement: 1-New York heart association(NYHA) measurement :NYHA scores range from I (no symptoms of heart failure ) to IV (symptoms at rest) 2- Physical performance of patients was assessed using the 6-minute walk test (6MWT) according to the protocol of Guyatt and colleagues.	—

Measure

Time frame

NewYork Heart Association functional class, Physical performance( 6 minutes walk test distance). Timepoint: Before intervention and after completion of intervention. Method of measurement: 1-New York heart association(NYHA) measurement :NYHA scores range from I (no symptoms of heart failure ) to IV (symptoms at rest) 2- Physical performance of patients was assessed using the 6-minute walk test (6MWT) according to the protocol of Guyatt and colleagues.

—

Secondary

Measure	Time frame
Serum level of N terminal pro -brain natreuretic peptide. Timepoint: before intervention and at the intervention completion. Method of measurement: enzyme immunoassay.;Quality of life. Timepoint: before intervention and at the intervention completion. Method of measurement: Iranian quality of life questionnaire (IHF-QOL).;Echocardiographic data: left ventricular ejection fraction ,Left ventircular end diastolic and systolic dimentions,left ventricular global longitudinal strain. Timepoint: before intervention and at the intervention completion. Method of measurement: Echocardiographic machine.	—

Measure

Time frame

Serum level of N terminal pro -brain natreuretic peptide. Timepoint: before intervention and at the intervention completion. Method of measurement: enzyme immunoassay.;Quality of life. Timepoint: before intervention and at the intervention completion. Method of measurement: Iranian quality of life questionnaire (IHF-QOL).;Echocardiographic data: left ventricular ejection fraction ,Left ventircular end diastolic and systolic dimentions,left ventricular global longitudinal strain. Timepoint: before intervention and at the intervention completion. Method of measurement: Echocardiographic machine.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoma Bahrami

Islamic Azad University

bahramihoma4@gmail.com+98 21 8249 9612

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026